公开(公告)号：EP1127140A2

公开(公告)日：2001-08-29

申请号：EP99958742.1

申请日：1999-11-05

申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE

发明人： CLEMONS, Paul, A. ,  GLADSTONE, Brian, G. ,  SETH, Abhinav ,  SCHREIBER, Stuart, L.

IPC分类号： C12N15/62 ,  C12N15/52 ,  C12N9/16 ,  C12N15/86 ,  A01K67/027 ,  G01N33/566

CPC分类号： C07D498/18 ,  A01K67/0271 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/09 ,  C07K2319/43 ,  C07K2319/71 ,  C07K2319/715 ,  C12N9/16 ,  C12N9/90 ,  C12N15/62 ,  C12N2710/16622

摘要： This invention provides methods and materials for making and using genetically engineered cells which are responsive to the presence of an FKBP/CAB ligand or a cyclophilin/CAB ligand. The invention relies upon the introduction into cells of recombinant DNAs encoding fusion proteins which are capable of forming a complex with each other in the presence of ligand. One of the fusion proteins contains a calcineurin A/calcineurin B domain (CAB) and at least one heterologous protein domain. The second fusion protein contains a domain derived from an FKBP protein which is capable of binding to an FKBP/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein may alternatively contain a cyclophilin domain which is capable of binding cyclosporin or other cyclophilin/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein also contains at least one heterologous domain.